Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1140957

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the side-effects of the drug metamizole.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280288
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280289 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1140958

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Spain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will have discussions with his Spanish counterpart on the effect of dispensing metamizole to (a) UK and (b) Spanish residents in Spain.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280289
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1140960

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Spain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to raise awareness of the potential side-effects of the drug metamizole among UK citizens and tourists in Spain.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280290
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280289 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1128562

registered interest
date	23/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Suicide
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 May 2019 to Question 254804, when the National Suicide Prevention Strategy will be published.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	257737
answer	answer is ministerial correction date of answer 05/06/2019 answer text <p>The National Suicide Prevention Strategy was first published in 2012 as the cross-Government outcomes strategy, ‘Preventing Suicide in England’.</p><p>We have published a number of progress reports since then with the third progress report, published in January 2017, updating the 2012 strategy in a number of areas. The latest progress report was published in January 2019 together with a cross-Government suicide prevention workplan which sets out an ambitious programme across central and local government and delivery agencies to reduce suicide. These documents are available at the following link:</p><p><a href="http://www.gov.uk/government/collections/suicide-prevention-resources-and-guidance" target="_blank">www.gov.uk/government/collections/suicide-prevention-resources-and-guidance</a></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 05/06/2019 13:44:23 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1126957

registered interest
date	15/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Suicide
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 April 2019 to Question 247685 on Suicide, how many local authorities have policies to tackle financial difficulty in their suicide prevention plans.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	254804
answer	answer is ministerial correction date of answer 20/05/2019 answer text <p>The Government consulted on the Breathing Space programme between October 2018 and January 2019. Breathing Space is a statutory debt repayment plan which aims to give people in problem debt the opportunity to take control of their finances and put them on a sustainable footing. The scheme includes a specific mechanism to make it easier for people experiencing a mental health crisis to access support. A response to the consultation will be published in due course.</p><p>The National Suicide Prevention Strategy highlights groups that need tailored approaches to address their mental health needs to reduce their suicide risk, including people who are vulnerable due to social or economic circumstances. We are working with the local government sector to assess the effectiveness of those plans, and a report will be published shortly that highlights areas of best practice and areas for improvement. This report will include an analysis of the extent to which local authority plans are addressing high risk groups.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/05/2019 14:13:53 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger